Announcements Trials

Browse Landscape

Phase

Phase 2 18 Phase 1/2 4 Phase 1 4 Phase 4 1 Phase 3 1

Status

Enrolling by invitation 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Non-Small-Cell Lung 31 Lung Neoplasms 9 Small Cell Lung Carcinoma 7 Biliary Tract Neoplasms 7 Carcinoma, Hepatocellular 6 Urinary Bladder Neoplasms 4 Liver Neoplasms 4 Carcinoma 4 Neoplasm Metastasis 3 Breast Neoplasms 3 Squamous Cell Carcinoma of Head and Neck 2 Small Cell Lung Carcinoma Extensive Disease 2 Recurrence 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Non-Muscle Invasive Bladder Neoplasms 2 Gallbladder Neoplasms 2 Endometrial Neoplasms 2 Carcinoma, Renal Cell 2 Urothelial Cancer 1 Sarcoma 1 Radiation Pneumonitis 1 Pancoast Syndrome 1 Ovarian Neoplasms 1 Oropharyngeal Neoplasms 1 Non Small Cell Lung Carcinoma NSCLC 1 Non Small Cell Lung Cancer NSCLC 1 Non - Small Cell Lung Cancer NSCLC 1 Neoplasms 1 Mesothelioma, Malignant 1 Mesothelioma 1

Interventions

Paclitaxel 20 Gemcitabine 16 Dexamethasone 16 Bevacizumab 16 Docetaxel 15 Oxaliplatin 14 Cyclophosphamide 13 Carboplatin 12 Capecitabine 12 Sorafenib 11 Fluorouracil 11 Leucovorin 10 Cisplatin 10 pembrolizumab 9 Pemetrexed 9 Epoetin Alfa 9 venetoclax 8 Prednisone 8 Fentanyl 8 Drug Therapy 8 Doxorubicin 8 atezolizumab 7 Rivaroxaban 7 Rituximab 7 Darbepoetin alfa 7 Anastrozole 7 Panitumumab 6 Ondansetron 6 Morphine 6 Irinotecan 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Neoplasms × durvalumab × Clear all

NCT05303532 2026-05-19

ROSY-D

AstraZeneca

Phase 3 Enrolling by invitation

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡